Effect of psoriasis activity on epidermal growth factor (EGF) and the concentration of soluble EGF receptor in serum and plaque scales

Clinical and Experimental Dermatology

Volumn 39, Issue 4, 2014, Pages 461-467

  Flisiak, I ^a   Szterling Jaworowska, M ^a   Baran, A ^a   Rogalska Taranta, M ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; SALICYLIC ACID; SOLUBLE EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG; DITHRANOL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; BLOOD LEVEL; CLINICAL EVALUATION; CORRELATION ANALYSIS; DESQUAMATION; DIAGNOSTIC KIT; ERYTHEMA; FOLLOW UP; PATHOGENESIS; PSORIASIS VULGARIS; STATISTICAL SIGNIFICANCE; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; EPIDERMAL GROWTH FACTOR; ERBB RECEPTORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84900456542     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12356     Document Type: Article

References (20)

1. Green L,. An overview and update of psoriasis. Nurs Stand 2011; 25: 47-55.
2. Krueger JG, Krane JF, Carter DM, Gottlieb AB,. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol 1990; 94 (Suppl 6): 135-40.
3. Flisiak I, Zaniewski P, Rogalska M, et al,. Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. Cytokine 2010; 52: 225-9.
4. Flisiak I, Zaniewski P, Rogalska-Taranta M, Chodynicka B,. Effect of psoriasis therapy on VEGF and its soluble receptors serum concentrations. J Eur Acad Dermatol Venereol 2012; 26: 302-7.
5. Wieduwilt MJ, Moasser MM,. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008; 65: 1566-84.
6. Mascia F, Cataisson C, Lee TC, et al,. EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo. J Invest Dermatol 2010; 130: 682-93.
7. Schneider MR, Werner S, Paus R, Wolf E,. Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology. Am J Pathol 2008; 173: 14-24.
8. Pietrzak A, Miturski R, Krasowska D, et al,. Concentration of an epidermal growth factor in blood serum of males during topical treatment of psoriasis. J Eur Acad Dermatol Venereol 1999; 12: 1-5.
9. Ma LL, Chen PF, Luo F,. Impact of serum epidermal growth factor on progressive psoriasis vulgaris and regulation of Chinese herbal medicine for cleaving heat, cooling blood, and detoxicating on it. Zhongguo Zhong Xi Yi Jie He Za Zhi 2008; 28: 733-5.
10. Anderson KS, Petersson S, Wong J, et al,. Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br J Dermatol 2010; 163: 1085-9.
11. Nanney LB, Stoscheck CM, King LE,. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984; 83: 385-93.
12. Green MR, Couchman JR,. Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. J Invest Dermatol 1985; 85: 239-45.
13. Stoll SW, Elder JT,. Retinoid regulation of heparin-binding EGF-like growth factor gene expression in human keratinocytes and skin. Exp Dermatol 1998; 7: 391-7.
14. Varani J, Kang S, Stoll S, Elder JT,. Human psoriatic skin in organ culture: comparison with normal skin exposed to exogenous growth factors and effects of an antibody to the EGF receptor. Pathobiology 1998; 66: 253-9.
15. Hsieh WL, Lin YK, Tsai CN, et al,. Indirubin, an acting component of indigo naturalis, inhibits EGFR activation and EGF-induced CDC25B gene expression in epidermal keratinocytes. J Dermatol Sci 2012; 67: 140-6.
16. Wu NL, Huang DY, Hsieh SL, et al,. EGFR-driven up-regulationof decoy receptor 3 in keratinocytes contributes to the pathogenesis of psoriasis. Biochim Biophys Acta 2013; 1832: 1538-48.
17. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
18. Wierzbicka E, Tourani JM, Guillet G,. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis? Br J Dermatol 2006; 155: 213-14.
19. Overbeck TR, Griesinger F,. Two cases of psoriasis responding to erlotinib: time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy? Dermatology 2012; 225: 179-82.
20. Petch D, Anderson RJ, Cunningham A, et al,. Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis. Bioorg Med Chem 2012; 20: 5901-14.